SCHEDULE: South Lake Entities Cut Rani Therapeutics Stake Below 5%

South Lake Management and its affiliates have reduced their beneficial ownership in Rani Therapeutics Holdings, Inc. to below 5% through recent open-market sales.

Summary

• South Cone Investments Limited Partnership, South Lake One LLC, and South Lake Management LLC (collectively, the 'Reporting Persons') filed Amendment No. 5 to their Schedule 13D.
• The filing reports a significant reduction in their beneficial ownership of Rani Therapeutics Holdings, Inc.'s Class A Common Stock.
• Prior to the reported sales, the Reporting Persons beneficially owned 2,379,194 shares, representing 4.9% of the outstanding Class A Common Stock.
• On October 20, 2025, South Lake One LLC sold 1,923,000 shares for approximately $4.6 million at a weighted average price of $2.4115 per share.
• On October 21, 2025, South Lake One LLC sold an additional 4,000,000 shares for approximately $11.1 million at a weighted average price of $2.7685 per share.
• As of October 21, 2025, the Reporting Persons ceased to be beneficial owners of more than 5% of the outstanding Class A Common Stock.
• The percentage of ownership is based on 47,898,228 shares of Class A Common Stock outstanding as of August 4, 2025, as reported by the Issuer in its Form 10-Q filed on August 7, 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative due to a significant institutional investor reducing its stake below the 5% threshold, often interpreted as a lack of conviction or a strategic exit, which can put downward pressure on the stock price.

Negatives

• A significant institutional investor group has reduced its stake in Rani Therapeutics Holdings, Inc. to below the 5% threshold, potentially signaling a decrease in confidence or a strategic exit.
• The sale of 5,923,000 shares over two days represents a substantial divestment by the Reporting Persons.

Risks

• The Reporting Persons explicitly state their intention to review their investment regularly and may, at any time, acquire additional securities, dispose of all or a portion of their holdings, or enter into derivative transactions, which introduces uncertainty regarding future share price movements.
• Further sales by the Reporting Persons could exert downward pressure on the stock price.

Future Outlook

The Reporting Persons intend to regularly review their investment in Rani Therapeutics Holdings, Inc. and may, at any time, decide to acquire additional securities, dispose of all or a portion of their holdings, enter into privately negotiated derivative transactions to hedge market risk, or take any other available course of action. These decisions will consider factors such as the Issuer's business and prospects, general economic conditions, and financial and stock market conditions.

Industry Context

This filing reflects a standard institutional investor action of adjusting portfolio exposure. While not indicative of broader industry trends, significant divestments by large holders can influence market perception of a company within its sector.

Stakeholder Impact

• Shareholders may perceive the reduction in institutional ownership as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.
• The company's management might face questions regarding the reasons for the significant investor's divestment.

Next Steps

• The Reporting Persons may acquire additional securities of the Issuer.
• The Reporting Persons may dispose of all or a portion of their remaining securities.
• The Reporting Persons may enter into privately negotiated derivative transactions to hedge market risk.
• The Reporting Persons may take any other available course of action, considering various market and company-specific factors.

Key Dates

Recommendation

The significant reduction in beneficial ownership by a major institutional investor group, bringing their stake below the 5% threshold, is a strong negative signal. Such a divestment often indicates a loss of confidence or a strategic shift away from the company by a sophisticated investor. This action could lead to further selling pressure and a decline in the stock price, making a 'sell' recommendation appropriate for investors looking to avoid potential downside.

Keywords

Rani Therapeutics, RTHT, Schedule 13D, beneficial ownership, stake reduction, institutional investor, South Lake Management, Class A Common Stock